{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,2]],"date-time":"2026-04-02T18:09:18Z","timestamp":1775153358765,"version":"3.50.1"},"reference-count":22,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2022,12,30]],"date-time":"2022-12-30T00:00:00Z","timestamp":1672358400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2022,12,30]],"date-time":"2022-12-30T00:00:00Z","timestamp":1672358400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100000892","name":"Prostate Cancer Foundation","doi-asserted-by":"publisher","award":["20YOUN11"],"award-info":[{"award-number":["20YOUN11"]}],"id":[{"id":"10.13039\/100000892","id-type":"DOI","asserted-by":"publisher"}]},{"name":"SPORE Career Enhancement Program"},{"name":"Rogel Cancer Center Medical Student Scholarship"},{"DOI":"10.13039\/100008456","name":"A. Alfred Taubman Medical Research Institute","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100008456","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000054","name":"U.S. Department of Health & Human Services | NIH | National Cancer Institute","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Early Detection Research Network"},{"DOI":"10.13039\/100000048","name":"American Cancer Society","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000048","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000011","name":"Howard Hughes Medical Institute","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000011","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Prostate Cancer Prostatic Dis"],"published-print":{"date-parts":[[2023,9]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Men with persistent risk of Grade Group (GG)\u2009\u2265\u20092 cancer after a negative biopsy present a unique clinical challenge. The validated MyProstateScore test is clinically-available for pre-biopsy risk stratification. In biopsy-na\u00efve patients, we recently validated a straightforward testing approach to rule-out GG\u2009\u2265\u20092 cancer with 98% negative predictive value (NPV) and 97% sensitivity. In the current study, we established a practical MPS-based testing approach in men with a previous negative biopsy being considered for repeat biopsy.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>Patients provided post-digital rectal examination urine prior to repeat biopsy. MyProstateScore was calculated using the validated, locked model including urinary PCA3 and TMPRSS2:ERG scores with serum PSA. In a clinically-appropriate primary (i.e., training) cohort, we identified a lower (rule-out) threshold approximating 90% sensitivity and an upper (rule-in) threshold approximating 80% specificity for GG\u2009\u2265\u20092 cancer. These thresholds were applied to an external validation cohort, and performance measures and clinical outcomes associated with their use were calculated.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>MyProstateScore thresholds of 15 and 40 met pre-defined performance criteria in the primary cohort (422 patients; median PSA 6.4, IQR 4.3\u20139.1). In the 268-patient validation cohort, 25 men (9.3%) had GG\u2009\u2265\u20092 cancer on repeat biopsy. The rule-out threshold of 15 provided 100% NPV and sensitivity for GG\u2009\u2265\u20092 cancer and would have prevented 23% of unnecessary biopsies. Use of MyProstateScore &gt;40 to rule-in biopsy would have prevented 67% of biopsies while maintaining 95% NPV. In the validation cohort, the prevalence of GG\u2009\u2265\u20092 cancer was 0% for MyProstateScore 0\u201315, 6.5% for MyProstateScore 15\u201340, and 19% for MyProstateScore &gt;40.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>In patients who previously underwent a negative prostate biopsy, the MyProstateScore values of 15 and 40 yielded clinically-actionable rule-in and rule-out risk groups. Using this straightforward testing approach, MyProstateScore can meaningfully inform patients and physicians weighing the need for repeat biopsy.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1038\/s41391-022-00633-3","type":"journal-article","created":{"date-parts":[[2022,12,30]],"date-time":"2022-12-30T05:15:42Z","timestamp":1672377342000},"page":"563-567","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":12,"title":["MyProstateScore in men considering repeat biopsy: validation of a simple testing approach"],"prefix":"10.1038","volume":"26","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-7614-9931","authenticated-orcid":false,"given":"Jeffrey J.","family":"Tosoian","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michael S.","family":"Sessine","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bruce J.","family":"Trock","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7044-9688","authenticated-orcid":false,"given":"Ashley E.","family":"Ross","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Cassie","family":"Xie","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yingye","family":"Zheng","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4158-552X","authenticated-orcid":false,"given":"Nathan L.","family":"Samora","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Javed","family":"Siddiqui","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yashar","family":"Niknafs","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6349-2431","authenticated-orcid":false,"given":"Zoey","family":"Chopra","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Scott","family":"Tomlins","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lakshmi P.","family":"Kunju","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ganesh S.","family":"Palapattu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Todd M.","family":"Morgan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"John T.","family":"Wei","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Simpa S.","family":"Salami","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Arul M.","family":"Chinnaiyan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2022,12,30]]},"reference":[{"key":"633_CR1","doi-asserted-by":"publisher","first-page":"1325","DOI":"10.1016\/j.juro.2008.06.022","volume":"180","author":"N Tan","year":"2008","unstructured":"Tan N, Lane BR, Li J, Moussa AS, Soriano M, Jones JS. Prostate cancers diagnosed at repeat biopsy are smaller and less likely to be high grade. J Urol. 2008;180:1325\u20139.","journal-title":"J Urol"},{"key":"633_CR2","doi-asserted-by":"publisher","first-page":"1767","DOI":"10.1016\/j.juro.2015.12.079","volume":"195","author":"A ElShafei","year":"2016","unstructured":"ElShafei A, Nyame Y, Kara O, Badawy A, Amujiogu I, Fareed K, et al. More Favorable Pathological Outcomes in Men with Low Risk Prostate Cancer Diagnosed on Repeat versus Initial Transrectal Ultrasound Guided Prostate Biopsy. J Urol. 2016;195:1767\u201372.","journal-title":"J Urol"},{"key":"633_CR3","doi-asserted-by":"crossref","unstructured":"Kearns JT, Lin DW. Utilizing Biomarkers in Patients with Prior Negative Prostate Biopsy. In: Chang SS, Cookson MS, editors. Prostate Cancer: Clinical Case Scenarios. Springer; 2018. p. 43\u201352.","DOI":"10.1007\/978-3-319-78646-9_3"},{"key":"633_CR4","doi-asserted-by":"publisher","first-page":"435","DOI":"10.1038\/nrurol.2015.159","volume":"12","author":"ML Blute Jr","year":"2015","unstructured":"Blute ML Jr, Abel EJ, Downs TM, Kelcz F, Jarrard DF. Addressing the need for repeat prostate biopsy: new technology and approaches. Nat Rev Urol. 2015;12:435\u201344.","journal-title":"Nat Rev Urol"},{"key":"633_CR5","doi-asserted-by":"crossref","unstructured":"Nordstrom T, Adolfsson J, Gronberg H, Eklund M. Repeat Prostate-Specific Antigen Tests Before Prostate Biopsy Decisions. J Natl Cancer Inst. 2016;108:435\u201344.","DOI":"10.1093\/jnci\/djw165"},{"key":"633_CR6","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1016\/j.eururo.2015.04.039","volume":"70","author":"SA Tomlins","year":"2016","unstructured":"Tomlins SA, Day JR, Lonigro RJ, Hovelson DH, Siddiqui J, Kunju LP, et al. Urine TMPRSS2:ERG Plus PCA3 for Individualized Prostate Cancer Risk Assessment. Eur Urol. 2016;70:45\u201353.","journal-title":"Eur Urol"},{"key":"633_CR7","doi-asserted-by":"publisher","first-page":"732","DOI":"10.1097\/JU.0000000000001430","volume":"205","author":"JJ Tosoian","year":"2021","unstructured":"Tosoian JJ, Trock BJ, Morgan TM, Salami SS, Tomlins SA, Spratt DE, et al. Use of the MyProstateScore Test to Rule Out Clinically Significant Cancer: Validation of a Straightforward Clinical Testing Approach. J Urol. 2021;205:732\u20139.","journal-title":"J Urol"},{"key":"633_CR8","doi-asserted-by":"publisher","first-page":"4.e1","DOI":"10.1016\/j.urolonc.2021.09.007","volume":"40","author":"NW Eyrich","year":"2022","unstructured":"Eyrich NW, Wei JT, Niknafs YS, Siddiqui J, Ellimoottil C, Salami SS, et al. Association of MyProstateScore (MPS) with prostate cancer grade in the radical prostatectomy specimen. Urol Oncol. 2022;40:4.e1\u20137.","journal-title":"Urol Oncol"},{"key":"633_CR9","doi-asserted-by":"publisher","first-page":"4071","DOI":"10.1002\/cncr.29611","volume":"121","author":"S Merdan","year":"2015","unstructured":"Merdan S, Tomlins SA, Barnett CL, Morgan TM, Montie JE, Wei JT, et al. Assessment of long-term outcomes associated with urinary prostate cancer antigen 3 and TMPRSS2:ERG gene fusion at repeat biopsy. Cancer. 2015;121:4071\u20139.","journal-title":"Cancer."},{"key":"633_CR10","doi-asserted-by":"publisher","first-page":"3091","DOI":"10.21037\/tau-20-1151","volume":"10","author":"NW Eyrich","year":"2021","unstructured":"Eyrich NW, Morgan TM, Tosoian JJ. Biomarkers for detection of clinically significant prostate cancer: contemporary clinical data and future directions. Transl Androl Urol. 2021;10:3091\u2013103.","journal-title":"Transl Androl Urol"},{"key":"633_CR11","doi-asserted-by":"publisher","first-page":"358","DOI":"10.1016\/j.eururo.2018.12.014","volume":"75","author":"M Assel","year":"2019","unstructured":"Assel M, Sjoberg D, Elders A, Wang X, Huo D, Botchway A, et al. Guidelines for Reporting of Statistics for Clinical Research in Urology. Eur Urol. 2019;75:358\u201367.","journal-title":"Eur Urol"},{"key":"633_CR12","doi-asserted-by":"crossref","unstructured":"Ferraro S, Bussetti M, Bassani N, Rossi RS, Incarbone GP, Bianchi F, et al. Definition of Outcome-Based Prostate-Specific Antigen (PSA) Thresholds for Advanced Prostate Cancer Risk Prediction. Cancers. 2021;13:3381.","DOI":"10.3390\/cancers13143381"},{"key":"633_CR13","doi-asserted-by":"publisher","first-page":"268","DOI":"10.1016\/j.eururo.2019.05.013","volume":"76","author":"MR Cooperberg","year":"2019","unstructured":"Cooperberg MR, Carroll PR, Dall\u2019Era MA, Davies BJ, Davis JW, Eggener SE, et al. The State of the Science on Prostate Cancer Biomarkers: The San Francisco Consensus Statement. Eur Urol. 2019;76:268\u201372.","journal-title":"Eur Urol"},{"key":"633_CR14","doi-asserted-by":"publisher","first-page":"4066","DOI":"10.1200\/JCO.2013.52.8505","volume":"32","author":"JT Wei","year":"2014","unstructured":"Wei JT, Feng Z, Partin AW, Brown E, Thompson I, Sokoll L, et al. Can urinary PCA3 supplement PSA in the early detection of prostate cancer? J Clin Oncol. 2014;32:4066\u201372.","journal-title":"J Clin Oncol"},{"key":"633_CR15","unstructured":"Williams BA, Mandrekar JN, Mandrekar SJ, Cha SS, Furth AF. Finding Optimal Cutpoints for Continuous Covariates with Binary and Time-to-Event Outcomes. Tech Rep Ser. 2006;79:1\u201327."},{"key":"633_CR16","doi-asserted-by":"publisher","first-page":"i6","DOI":"10.1136\/bmj.i6","volume":"352","author":"AJ Vickers","year":"2016","unstructured":"Vickers AJ, Van Calster B, Steyerberg EW. Net benefit approaches to the evaluation of prediction models, molecular markers, and diagnostic tests. BMJ. 2016;352:i6.","journal-title":"BMJ."},{"key":"633_CR17","doi-asserted-by":"publisher","DOI":"10.1186\/s12894-020-00712-4","volume":"20","author":"J McKiernan","year":"2020","unstructured":"McKiernan J, Noerholm M, Tadigotla V, Kumar S, Torkler P, Sant G, et al. A urine-based Exosomal gene expression test stratifies risk of high-grade prostate Cancer in men with prior negative prostate biopsy undergoing repeat biopsy. BMC Urol. 2020;20:138.","journal-title":"BMC Urol"},{"key":"633_CR18","doi-asserted-by":"publisher","first-page":"917","DOI":"10.1056\/NEJMoa1910038","volume":"382","author":"M Ahdoot","year":"2020","unstructured":"Ahdoot M, Wilbur AR, Reese SE, Lebastchi AH, Mehralivand S, Gomella PT, et al. MRI-Targeted, Systematic, and Combined Biopsy for Prostate Cancer Diagnosis. N Engl J Med. 2020;382:917\u201328.","journal-title":"N Engl J Med"},{"key":"633_CR19","doi-asserted-by":"publisher","first-page":"402","DOI":"10.1016\/j.eururo.2020.03.048","volume":"78","author":"NJ Sathianathen","year":"2020","unstructured":"Sathianathen NJ, Omer A, Harriss E, Davies L, Kasivisvanathan V, Punwani S, et al. Negative Predictive Value of Multiparametric Magnetic Resonance Imaging in the Detection of Clinically Significant Prostate Cancer in the Prostate Imaging Reporting and Data System Era: A Systematic Review and Meta-analysis. Eur Urol. 2020;78:402\u201314.","journal-title":"Eur Urol"},{"key":"633_CR20","doi-asserted-by":"publisher","first-page":"592","DOI":"10.1016\/j.euf.2017.11.010","volume":"5","author":"GA Sonn","year":"2019","unstructured":"Sonn GA, Fan RE, Ghanouni P, Wang NN, Brooks JD, Loening AM, et al. Prostate Magnetic Resonance Imaging Interpretation Varies Substantially Across Radiologists. Eur Urol Focus. 2019;5:592\u20139.","journal-title":"Eur Urol Focus"},{"key":"633_CR21","doi-asserted-by":"publisher","first-page":"1111","DOI":"10.1016\/j.jval.2021.02.009","volume":"24","author":"B Jiao","year":"2021","unstructured":"Jiao B, Gulati R, Hendrix N, Gore JL, Rais-Bahrami S, Morgan TM, et al. Economic Evaluation of Urine-Based or Magnetic Resonance Imaging Reflex Tests in Men With Intermediate Prostate-Specific Antigen Levels in the United States. Value Health. 2021;24:1111\u20137.","journal-title":"Value Health"},{"key":"633_CR22","doi-asserted-by":"publisher","first-page":"e2128646","DOI":"10.1001\/jamanetworkopen.2021.28646","volume":"4","author":"MS Leapman","year":"2021","unstructured":"Leapman MS, Wang R, Park HS, Yu JB, Sprenkle PC, Dinan MA, et al. Adoption of New Risk Stratification Technologies Within US Hospital Referral Regions and Association With Prostate Cancer Management. JAMA Netw Open. 2021;4:e2128646.","journal-title":"JAMA Netw Open"}],"container-title":["Prostate Cancer and Prostatic Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41391-022-00633-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41391-022-00633-3","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41391-022-00633-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,8,24]],"date-time":"2023-08-24T10:07:52Z","timestamp":1692871672000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41391-022-00633-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,12,30]]},"references-count":22,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2023,9]]}},"alternative-id":["633"],"URL":"https:\/\/doi.org\/10.1038\/s41391-022-00633-3","relation":{"has-preprint":[{"id-type":"doi","id":"10.21203\/rs.3.rs-1728404\/v1","asserted-by":"object"}]},"ISSN":["1365-7852","1476-5608"],"issn-type":[{"value":"1365-7852","type":"print"},{"value":"1476-5608","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,12,30]]},"assertion":[{"value":"5 June 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 November 2022","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 December 2022","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 December 2022","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"JJT and AMC are advisors with equity interest in LynxDx. MSS and YZ are consultants to LynxDx. AMC and SAT are co-inventors on a patent issued to The University of Michigan (UM) on ETS gene fusions in prostate cancer and are included in the royalty distribution stream (managed by UM). The patent is currently licensed to LynxDx.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"Institutional review board approval was obtained at participating sites, and all patients provided informed consent. This study was performed in accordance with the Declaration of Helsinki.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}}]}}